Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

Three biotechs dis­closed pull­backs on sick­le cell dis­ease R&D in the span of 16 hours: with Graphite Bio end­ing work, Sang­amo Ther­a­peu­tics search­ing for a pro­gram part­ner and In­tel­lia Ther­a­peu­tics say­ing No­var­tis re­neged on an ear­ly-phase clin­i­cal tri­al.

The pipeline rewrites come as Ver­tex and part­ner CRISPR Ther­a­peu­tics wrap up an ap­proval re­quest for their ex vi­vo gene-edit­ed ther­a­py and as blue­bird bio sends in the pa­per­work for an FDA green light of its gene ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.